{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-080923","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2025-08-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.417769+00:00","generated_at":"2026-05-17T09:47:41.759265+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Allarity receives FDA Fast Track for stenoparib in advanced ovarian cancer","bullets":["FDA granted Fast Track designation to stenoparib for advanced ovarian cancer on August 26, 2025.","Fast Track enables expedited development, potential accelerated/priority review and rolling review.","Company began Phase 2 enrollment in June 2025; several patients already dosed.","Prior Phase 2 data showed durable clinical benefit including patients on treatment >22 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-080923","json":"https://secwatch.observer/filing/0001213900-25-080923.json","markdown":"https://secwatch.observer/filing/0001213900-25-080923.md","text":"https://secwatch.observer/filing/0001213900-25-080923.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390025080923/0001213900-25-080923-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390025080923/ea0254632-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T09:47:41.759265+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}